Shuanglin Co., Ltd. (300100.SZ) plans to repurchase company shares for 50 million to 100 million yuan.
Shuanglin Co., Ltd. (300100.SZ) announced that the company intends to use its own funds or funds raised by itself to repurchase part of the issued ordinary shares (A-shares) through a centralized bidding approach. The repurchased shares will be used to implement the employee stock ownership plan or equity incentive plan. The total amount of funds for the repurchase will not be less than 50 million yuan (inclusive) and not exceed 100 million yuan (inclusive), with a repurchase price not exceeding 35 yuan per share (inclusive).
Shuanglin Co., Ltd. (300100.SZ) announced that the company plans to use its own funds or self-raised funds to repurchase a portion of the issued ordinary shares (A shares) through a centralized bidding method. The repurchased shares will be used to implement the employee stock ownership plan or equity incentive plan. The total amount of funds for the repurchase will not be less than 50 million yuan (inclusive) and will not exceed 100 million yuan (inclusive), with a repurchase price not exceeding 35 yuan per share (inclusive).
Related Articles
US Stock Market Move | ZAI LAB (ZLAB.US) surged over 12%, with Q2 product revenue increasing by 11% quarter-on-quarter.
NETJOY (02131) announced its performance for the fiscal year 2025, reporting a loss attributable to equity holders of the parent company of 48.028 million yuan, a year-on-year reduction of 89.55%.
EDDING GENOR (06998): Completion of drug administration for the first subject in the Phase II clinical trial of GB268.
US Stock Market Move | ZAI LAB (ZLAB.US) surged over 12%, with Q2 product revenue increasing by 11% quarter-on-quarter.
NETJOY (02131) announced its performance for the fiscal year 2025, reporting a loss attributable to equity holders of the parent company of 48.028 million yuan, a year-on-year reduction of 89.55%.
EDDING GENOR (06998): Completion of drug administration for the first subject in the Phase II clinical trial of GB268.
RECOMMEND
